aRCC: 1L Treatment Options and Patient Management

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

aRCC: 1L Treatment Options and Patient Management

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

By ASCO Genitourinary Cancers Symposium FEATURING Michael Dean

192 views

February 26, 2022

Comments 0

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

ASCO Genitourinary Cancers Symposium

S. Tykodi

186 views

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

Thomas Hutson

99 views

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

ASCO Genitourinary Cancers Symposium

R. McKay

77 views

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

ASCO Genitourinary Cancers Symposium

N. Haas

145 views

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 B…

ASCO 2022 Conference Coverage

L. Albiges

139 views

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…

Moffitt Cancer Center

J. Gao

249 views

2022 ASCO Renal Cell Carcinoma Updates

Total Health

M. Bupathi

198 views

Dual Immunotherapy in RCC

O'Neal Comprehensive Cancer Center at UAB

A. Basu

549 views

ESMO 2022 on the Latest in mRCC

ecancer

J. Puente, B. Escudier, V. Grünwald, S. Oudard

195 views

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

Mário Fontes-Sousa

230 views

Choosing Wisely: 1L Combination Treatment for Advanced RCC

Aly-Khan A. Lalani

749 views

ESMO 2022 Updates in Renal Cancer

ecancer

T. Choueiri

297 views

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

1.9K views

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Yale Cancer Center

D. Braun

468 views

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

PrecisCa

M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel

206 views